Theramir Ltd, a Limassol-based biotechnology company advancing miRNA-loaded extracellular vesicle therapeutics for aggressive and treatment-resistant cancers, has announced the appointment of Professor Sophia N. Karagiannis to its Scientific Advisory Board.
Professor Karagiannis is a globally recognised expert in translational cancer immunology and therapeutic antibody design. She currently serves as Professor of Translational Cancer Immunology and Immunotherapy at King’s College London, where she leads research on the development and clinical translation of engineered antibodies and immune biomarkers, particularly in solid tumours such as melanoma, ovarian, and breast cancer.
Her team was the first worldwide to design and evaluate IgE class antibodies for oncology, paving the way for novel immunotherapeutic strategies. As academic founder of Epsilogen Ltd, she helped establish the first immuno-oncology company focused on IgE therapies for cancer. She also co-founded and serves as Secretary of the international AllergoOncology Working Group, supported by the European Academy of Allergy and Clinical Immunology (EAACI), which explores the role of allergic immune responses in oncology and cancer therapy.
Her academic leadership and experience bridging early-stage discoveries with biotech translation are a powerful asset to Theramir. “We are honoured to welcome Professor Karagiannis to our Scientific Advisory Board,” said Dr Marianna Prokopi-Demetriades, Founder of Theramir Ltd. “Her expertise in therapeutic design, immune modulation, and translational research is highly aligned with our focus on validating the EVmiRÒ platform and advancing toward GMP-compliant production and early-stage clinical testing. Her experience guiding early-stage biotechs through complex development milestones will be invaluable as we prepare to bring our first-in-class miRNA-based therapies closer to patients with cancers like triple-negative breast cancer.”
Theramir’s EVmiR® platform uses mesenchymal stem cell-derived extracellular vesicles to deliver therapeutic microRNAs targeting key oncogenic and immune-regulatory pathways, including LCP-1, in tumours that lack effective targeted therapies. The platform has shown promising results in preclinical models of triple-negative breast, bladder, and pancreatic cancer, supporting its potential as a next-generation RNA-based therapy.
"With Professor Karagiannis joining its Scientific Advisory Board, Theramir strengthens its translational and immunological expertise as it prepares for GMP manufacturing and first-in-human studies," the company said in a press release.
